Entering text into the input field will update the search result below

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2021 Results Conference Call August 5, 2021 4:30 PM ET

Company Participants

Nicole Arndt - Senior Manager, IR

Ryan Spencer - CEO

Kelly MacDonald - CFO

Robert Janssen - CMO

Donn Casale - SVP, Commercial.

Conference Call Participants

Phil Nadeau - Cowen and Company

Matt Phipps - William Blair

Josh Schimmer - Evicore

Ed White - H.C. Wainwright


Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Second Quarter 2021 Conference Call. As a reminder, this conference call is being recorded. At the end of the Company's prepared remarks, we will open the call for questions and provide specific instructions at that point.

I would now like to turn the call over to Nicole Arndt, Senior Manager, Investor Relations, you may begin.

Nicole Arndt

Thank you, Anne. Good afternoon, and welcome to the Dynavax second quarter 2021 financial results and corporate update conference Call. Joining me on the call today are Ryan Spencer, Chief Executive Officer; Kelly MacDonald, Chief Financial Officer; Robert Janssen, Chief Medical Officer; and Donn Casale, Senior Vice President, Commercial.

Before I begin, I advise you that we will be making forward-looking statements today, including statements regarding revenue expectations and financial outlook, business performance expected revenue and margins, HEPLISAV-B's commercial profile, it's potentials become the standard of care, European launch timing, post marketing studies and other vaccine development with our collaborators. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. These risks are summarized in today's press release and are detailed in our Risk Factors section of our current 10-Q and 10-K periodic reports filed with the SEC, which we encourage you to review.

I will now turn the call over to Ryan Spencer, CEO of Dynavax.

Ryan Spencer

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About DVAX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on DVAX

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.